Document is current
Any future updates will be listed below
-
Authors
Sanno, Naoko
Urayama, Kevin Y. https://orcid.org/0000-0002-1360-9531
Mori, Joji
Yoshizawa, Kenichi
Hashimoto, Chie
-
Funding
Funding for this research was provided by:
Eli Lilly Japan
Daiichi Sankyo Company
- License Information
-
More Information
Article History
Received: 25 February 2026
Accepted: 12 May 2026
First Online: 23 May 2026
Declarations
:
: Naoko Sanno has received honoraria from Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., Otsuka Pharmaceutical Co., Ltd. and Amgen K.K. during the conduct of the study. Kevin Y. Urayama, Joji Mori, Kenichi Yoshizawa and Chie Hashimoto are employees of Eli Lilly Japan K.K. and minor stockholders of Eli Lilly and Company. Kenichi Yoshizawa is also a shareholder of Pfizer Inc., GSK plc., Merck & Co., Inc., and Kissei Pharmaceutical Co., Ltd.
: The study was conducted per ethical principles originating from the Declaration of Helsinki and was compliant with the Japanese “Ethical Guidelines for Medical and Biological Research Involving Human Subjects”. The study was approved by the Ethics Review Board of the Research Institute of Healthcare Data Science (Tokyo, Japan; Approval No. RI2022002). Before enrollment, patients received a detailed study explanation and provided informed consent, including agreement for information release. Only those who consented to participate and to this use of their personal devices were enrolled.
